
DongKook Pharmaceutical said on Monday through its quarterly report that its consolidated operating profit for the third quarter was 23.8 billion won, a decrease of 4.1% compared to the same period last year.
During the same period, revenue increased by 14.0% to 258.7 billion won, while net income decreased by 36.1% to 14.3 billion won.
The cumulative consolidated operating profit for the first three quarters was 77.2 billion won, an increase of 6.9% compared to the same period last year, and revenue rose by 12.4% to 768.6 billion won.
Net income decreased by 0.9% to 57.8 billion won. Consequently, it is expected that Dong-A Health & Pharma will surpass the 1st trillion won mark in annual revenue for the first time this year.
On a standalone basis, DongKook Pharmaceutical's third-quarter operating profit increased by 23.3% to 23.1 billion won compared to the same period last year, and revenue rose by 18.3% to 222.1 billion won.
Net income decreased by 33.3% to 10.9 billion won. On a cumulative basis, revenue was 658.6 billion won and operating profit was 70.9 billion won, representing increases of 17.2% and 23.3%, respectively, compared to the same period last year. Net income increased by 9.9% to 51.7 billion won.
DongKook Pharmaceutical said that its consolidated revenue growth rate was lower than its standalone figure due to sluggish sales at its subsidiary, Dongkuk Life Science.
A company official said, "The results of Dongkuk Life Science reflected the decline in sales in the Medical Equipment (ME) business segment caused by deteriorating conditions in the diagnostic equipment market, as well as decreases in revenue and profit arising from portfolio restructuring, including the relocation of a production plant for contrast agents (raw materials and finished products) for global exports."
The official added, "It is expected that management efficiency and profitability will improve once this business structure reorganization at Dongkuk Life Science is completed."
Looking solely at DongKook Pharmaceutical's own performance, the company explained that revenue from the overseas division of its Health & Beauty Business Division has begun to show substantial results, maintaining a high growth rate.
"Madeca Cream" surpassed 100 million units in cumulative sales as of September this year since its launch. The cumulative revenue for the "Centellian24" brand reached 1 trillion won from 2015 to 2024.
A company official said, "We are rapidly expanding distribution and brand touchpoints in major global markets such as North America, Europe, Japan, and Southeast Asia."
The official noted that the revenue growth rate of the Healthcare Business Division was 30.9% compared to the same period last year, with cosmetics (including beauty devices and exports) growing by 40%.
The official added, "We aim to leap forward as a global Health & Beauty company by expanding our overseas revenue share and informing global consumers of Dong-A Health & Pharma's technological capabilities and brand competitiveness."
In the pharmaceutical export sector, the outlook is bright due to factors such as the signing of supply and licensing agreements for the improved new drug compound for benign prostatic hyperplasia, "Uresco," in the Latin America region.
DongKook Pharmaceutical plans to sequentially commercialize products such as the prostate cancer treatment "Lorelin" (1-month and 3-month formulations) through pipelines (drug candidates) utilizing its proprietary DDS (Drug Delivery System) platform technologies, including microspheres, and open innovation with relevant institutional investors.
The company is also committed to maintaining its growth trajectory by developing and launching new pharmaceutical products, including obesity treatments, acromegaly treatments, and immunosuppressants.